-Liraglutide - GLP1 receptor agonist.jpg "(Des-Gly4)-Liraglutide - GLP1 receptor agonist")
-Liraglutide.jpg "(Des-Gly4)-Liraglutide - GLP1 receptor agonist")
SP-CAT-035
Projects
(Des-Gly4)-Liraglutide is a Liraglutide impurity. (Des-Gly4)-Liraglutide can be used for analytical method development, method validation and quality control during production of Liraglutide. For research use only, do not use in humans!
Glucagon-like Peptide 1 (GLP-1) and other GLP-1 receptor agonists have proven to be an effective treatment of Type 2 diabetes and obesity, offering significant benefits. They improve glycemic control by enhancing insulin secretion in response to elevated blood glucose levels; help reduce glucagon levels, further supporting blood sugar regulation; and slow gastric emptying, leading to weight loss, which is beneficial for diabetic patients who are obese. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides in all formats, scales and modifications to the global scientific community. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Benefits of JPT’s PeptidesReferences:
Read References with Specialty Peptides
Testimonial:
"Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle."
Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands
Testimonial:
Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.
Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands
| Properties | Values |
|---|---|
| Amount: | 0.5 mg net (50 x 10 µg) (AAA) |
| Application: | Diabetes research |
| Category: | Diabetes Peptides |
| Condition / Topic: | Diabetes |
| Layout: | Freeze-dried in plastic vial |
| Organism: | Artificial |
| Protein Name: | Diabetes Peptide |
| Purity: | >95% (HPLC-MS) |
| Quantification: | Yes |
| Information | Values |
|---|---|
| Sequence: | H-HAETFTSDVSSYLEGQAA-Lys(Palmitoyl-gammaGlu)-EFIAWLVRGRG-OH |
Check our list of products, click and go.
Get a quote-Liraglutide - GLP1 receptor agonist.jpg "(D-His1)-Liraglutide - GLP1 receptor agonist")